0 likes | 10 Views
A pharmaceutical company requested to conduct research for Long COVID outcomes using RWD to evaluate their productu2019s indication for treating neurological conditions for Long COVID. The aim was to understand COVID-19's impact on neurodegenerative conditions and identify biomarkers predicting Long COVID-associated neurodegenerative conditions.
E N D
CASE STUDY Understanding Impact of COVID-19 on Neurological Conditions via RWD
A pharmaceutical company requested to conduct research for Long COVID outcomes using RWD to evaluate their product’s indication for treating neurological conditions for Long COVID. The aim was to understand COVID-19's impact on neurodegenerative conditions and identify biomarkers predicting Long COVID-associated neurodegenerative conditions. THE CHALLENGE
HEALTHARK’S ROLE Analyzed Incidence of Long COVID Conditions Healthark assisted the client in analyzing the retrospective Real-World Data (RWD) using an open-source dataset to assess the incidence of Long COVID-related neurological conditions among patients who tested positive for COVID-19. Literature Review & Preliminary Research Cohort Foundation Analysis Execution
Over a six-month period, Healthark developed a framework of parameters for identifying potential biomarkers related to Long COVID. IMPACT